Pharmatest provides high quality services for efficacy testing of new drug candidates against such diseases as metastatic cancer, osteoporosis and certain inflammatory diseases. The company also offers models of human hormone action designed for the safety testing of various chemicals and substances according to the guidelines of new European Community Regulation on chemicals and their safe use (REACH).

This agreement establishes Pharmatest as Bayer Schering Pharma’s preferred provider within the field of services it offers.

Pharmatest already has a long-term collaboration with Bayer Schering Pharma AG and this preferred partnership now provides Pharmatest with new business opportunities with other Bayer units, such as Bayer Crop Sciences and Consumer Care. This preferred partnership agreement will make the initiation of new projects between the two companies faster and more flexible.

“There has been a steady increase in the amount of research projects with Bayer Schering Pharma AG and we hope there will be even more extensive demand for the company’s services now that the agreement has been signed”, said Pharmatest CEO Jussi Halleen, and concluded: “This agreement also ensures that Pharmatest will be able to respond to Bayer Schering Pharma’s research needs on a much broader spectrum.”